Scopus BioPharma Inc. (SCPS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -11.71 Million USD | 57.61% |
| 2021 | -27.63 Million USD | -172.13% |
| 2020 | -10.15 Million USD | -277.59% |
| 2019 | -2.68 Million USD | -292.04% |
| 2018 | -685.96 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -2.67 Million USD | -45.97% |
| 2023 Q2 | -2.92 Million USD | -9.3% |
| 2022 FY | - USD | 57.61% |
| 2022 Q4 | -1.83 Million USD | 3.3% |
| 2022 Q3 | -1.89 Million USD | 42.81% |
| 2022 Q2 | -3.31 Million USD | 28.78% |
| 2022 Q1 | -4.66 Million USD | 28.51% |
| 2021 Q3 | -2.75 Million USD | 81.94% |
| 2021 FY | - USD | -172.13% |
| 2021 Q1 | -3.07 Million USD | -330.53% |
| 2021 Q2 | -15.28 Million USD | -397.32% |
| 2021 Q4 | -6.51 Million USD | -136.22% |
| 2020 Q4 | -713.76 Thousand USD | 18.44% |
| 2020 Q1 | -618.88 Thousand USD | 35.75% |
| 2020 Q2 | -7.94 Million USD | -1183.75% |
| 2020 FY | - USD | -277.59% |
| 2020 Q3 | -875.1 Thousand USD | 88.99% |
| 2019 Q4 | -963.3 Thousand USD | -20.84% |
| 2019 FY | - USD | -292.04% |
| 2019 Q3 | -797.17 Thousand USD | -82.34% |
| 2019 Q2 | -437.18 Thousand USD | 11.08% |
| 2019 Q1 | -491.65 Thousand USD | 0.0% |
| 2018 Q1 | -122.48 Thousand USD | 0.0% |
| 2018 Q2 | -152.22 Thousand USD | -24.28% |
| 2018 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -2518.681% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 60.302% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 89.73% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 25.683% |
| Better Therapeutics, Inc. | -38.26 Million USD | 69.387% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 69.389% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 34.514% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 65.277% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 64.902% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 88.986% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -1182.265% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 63.94% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 74.914% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -106.081% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 28.145% |
| Molecular Templates, Inc. | 1.43 Million USD | 919.101% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 15.582% |
| NexImmune, Inc. | -28.16 Million USD | 58.416% |
| Orgenesis Inc. | -60.71 Million USD | 80.709% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 77.165% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -15854.491% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 27.452% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 97.831% |
| Statera Biopharma, Inc. | 38.93 Million USD | 130.084% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -70.15% |
| Trevena, Inc. | -35.28 Million USD | 66.807% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -20797.306% |
| Vaccinex, Inc. | -19.74 Million USD | 40.687% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -1018.758% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 75.005% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -61.271% |